One retrospective clinical report found that patients who received intra-articular BPC-157 injections for knee pain (many of whom had tendon/ligament or other musculoskeletal issues) reported subjective improvements in symptoms for more than six months afterward, which may reflect reduced inflammation and enhanced functional recovery in those injured tissues
This is the only growth hormone peptide with FDA approval and Phase III randomized trial data specifically demonstrating selective visceral fat reduction
That is exactly why they are used under medical supervision with realistic expectations, and why a provider, not a marketing page, should decide whether they fit your case
Johansen, P.B., et al., Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
Please note that the terms of sale are applicable